CAGAS
NTLA icon

Capital Advisory Group Advisory Services’s Intellia Therapeutics NTLA Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,233
Closed -$300K – 375
2021
Q3 		$300K Buy
+2,233
New +$338K 0.11% 155

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Advisory Group Advisory Services's NTLA Position: Q4 2021 in Review

Capital Advisory Group Advisory Services sold out of Intellia Therapeutics (NTLA) in Q4 2021, closing a stake of 2,233 shares — an estimated $300K sold.

Capital Advisory Group Advisory Services first reported a position in NTLA in Q3 2021 and held it in 1 quarter. The position peaked at $300K in Q3 2021. 371 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

  • Capital Advisory Group Advisory Services reported no remaining Intellia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Capital Advisory Group Advisory Services sold 2,233 Intellia Therapeutics shares in Q4 2021, an estimated $300K.
  • Capital Advisory Group Advisory Services first reported a position in Intellia Therapeutics in Q3 2021 and held it in 1 quarter.
  • Capital Advisory Group Advisory Services's Intellia Therapeutics position peaked at $300K in Q3 2021.
  • 371 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on Capital Advisory Group Advisory Services's 13F filing for Q4 2021, filed 15 Feb 2022.